Navigation Links
Using coxibs and NSAIDs to treat osteoarthritis
Date:8/13/2007

Mt Laurel, NJ 13 August 2007 - In an Editorial, to be published in the international journal Osteoarthritis and Cartilage (http://intl.elsevierhealth.com/journals/joca/), published by Elsevier, a panel of arthritis research experts has recommended that coxibs and nonsteroidal anti-inflammatory drugs (NSAIDs) must remain a significant part of the tool kit used in treating osteoarthritis (OA). The Editorial summarizes the outcomes of an international workshop organized by the Osteoarthritis Research Society International (OARSI) and the International COX-2 Study Group, held 2425 March 2007. The authors urge that an evidence-based approach must be taken when making recommendations to patients.

OA, the most common form of arthritis, is a major medical problem. It has been estimated that over 20 million Americans are afflicted with OA, and that number will rise to 40 million by the year 2020. Controversy now exists as to the safest and most efficacious way of treating the disease, particularly with respect to use of NSAIDs, both non-selective and selective (so-called COX-2 selective agents or coxibs). Adverse reactions related to the gastrointestinal tract, particularly with the non-selective NSAIDs, have been described; more recently, concerns have been expressed related to the cardiovascular system with both groups of agents.

A recent scientific statement from the American Heart Association (AHA) made recommendations with regard to the treatment of OA.1 A number of these recommendations are challenged in the Editorial2 in Osteoarthritis and Cartilage, with particular concern about their impact on appropriate use of these agents.

The Editorial questions the recommendation made in the AHA statement which described a stepped care approach to pharmacologic therapy for musculoskeletal diseases. The Editorial strongly recommends that several aspects of the AHA statement be reconsidered. For example, it urges that the AHA withdraw their non-evidence-based recommendations that high-dose aspirin be administered alone as a first line therapy for patients with chronic pain and arthritis.

Dr Roland W. Moskowitz, Professor of Medicine at Case Western Reserve University/University Hospitals of Cleveland, lead author of the Editorial comments, "Careful review of the pros and cons of using these agents, and the situations in which they are most safely and effectively used, is required to help us understand how best to take advantage of their availability".

The input by the OARSI/COX-2 International Study Group provides evidence-based background and guidance that will be of help to physicians, and to patients, in the use of these important commonly used agents.


'/>"/>
Contact: Ian Salusbury
ian.salusbury@elsevier.com
44-186-584-3000
Elsevier
Source:Eurekalert

Related medicine news :

1. Poor health care in Russia maybe causing Decline in its Population
2. Multi billion-dollar suit filed against cell phone firm for causing brain tumours
3. Researchers urge caution in using ear tube surgery
4. Ulcer causing bug found in stored food
5. Using Stem Cells To Treat Incontinence In Women
6. Flu-Drugs Are Causing Resistance Across The World
7. Researchers at Cornell University as been reported using research fund by false claims
8. Relief to pregnant women using fertility drugs
9. The hazards of using disinfectant hand gel
10. Colon cancer risk linked to genes causing Hemochromatosis
11. Teens Misusing Nicotine-Replacement Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream ... procedures, dermaka cream can be incorporated into the post-surgical treatment plans of a variety ... , dermaka cream is very effective for bruising and causes a rapid resolution ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Randall Markarian, DDS, are co-chairs for the Illinois State Dental Society (ISDS) Foundation’s ... 15-16 at the Gateway Convention Center in Collinsville. , They expect ...
(Date:6/24/2016)... ... June 24, 2016 , ... SpiritQuest Sedona Retreats, located in ... Sedona, surrounded by famous vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The ... the Lodge at Sedona as well as the Sedona Rouge, both popular accommodations for ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, a global ... for clinical transfusion research programs and for the blood supply in the Netherlands, ... Predictive Analytical Rating Score (PREPAReS) study. , Currently in its sixth year, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... The vast majority of dialysis patients currently ... are usually 3 times a week, with treatment times ... time, equipment preparation and wait time.  This regimen can ... patients who are elderly and frail.  Many elderly dialysis ... centers for some duration of time. Residents ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
(Date:6/23/2016)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a ... of primary and metastatic liver cancers, announces that the ... www.againsttheodds.eu - has been awarded a silver medal ... The website was developed as an education ... who are coping with the devastating diagnosis of cancer ...
Breaking Medicine Technology: